...
首页> 外文期刊>Journal of the National Cancer Institute >Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.
【24h】

Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.

机译:欧洲前列腺癌筛查随机研究(ERSPC)-鹿特丹中的间隔癌。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The interval cancer rate is an important parameter for determining the sensitivity of a screening procedure and the screening interval. We evaluated the time and mechanism of detection and the stage distribution of interval prostate cancers diagnosed during a 4-year screening interval. METHODS: We determined the rate of interval cancers and the sensitivity of the screening protocol (involving prostate-specific antigen, digital rectal and transrectal ultrasound examinations) in a cohort of 17 226 men (8350 on the screened arm, 8876 on the control arm) enrolled consecutively on the European Randomized Study of Screening for Prostate Cancer-Rotterdam. Men on the screened arm received a first screen between October 1993 and December 1996 and a scheduled second screen 4 years later. Prostate cancers detected in men enrolled on the control arm over the same 4-year period and, between screens, in men on the screened arm, were identified by linkage to the Dutch national cancer registry. RESULTS: During the first screen, 412 prostate cancers were detected. During the subsequent 4-year period, 135 cancers were diagnosed in men in the control arm and 25 cancers were diagnosed in men in the screened arm. Seven of the 25 cancers were diagnosed in men who had refused a recommended biopsy at their initial screen. Of the remaining 18 cancers, all were classified as stage T1A-C or T2A and none were poorly differentiated or metastatic. The rate of interval cancers relative to the number of cancers in the control group was 18.5% (25/135), or 13.3% (18/135), if the seven who refused an initial biopsy were excluded. The sensitivity of the screening protocol was 79.8% when considering all 25 interval cancers and 85.5% when considering 18 interval cancers. CONCLUSION: The interval cancer rate with a 4-year screening interval was low, confirming that the screening procedure has a high sensitivity and that the 4-year screening interval is reasonable.
机译:背景:间隔癌症发生率是确定筛查程序的敏感性和筛查间隔的重要参数。我们评估了在4年筛查间隔期间诊断出的间隔性前列腺癌的检测时间和机制以及阶段性分布。方法:我们确定了一组17 226名男性(筛查臂上为8350例,对照臂上为8876例)的人群间发性癌症的发生率和筛查方案的敏感性(涉及前列腺特异性抗原,直肠指检和经直肠超声检查)。连续入选《欧洲鹿特丹前列腺癌筛查随机研究》。被屏蔽的手臂上的男人在1993年10月至1996年12月之间接受了第一次放映,并在4年后获得了第二次放映。通过与荷兰国家癌症登记系统的关联,鉴定了在相同的4年时间内在对照组中登记的男性中检测到的前列腺癌,以及在两次筛查之间,在接受筛查的男性中发现的前列腺癌。结果:在第一次筛查中,检测到412例前列腺癌。在随后的4年中,对照组的男性被诊断出135例癌症,被筛查的男性被诊断出25例癌症。 25例癌症中有7例是在最初筛查时拒绝推荐活检的男性中诊断出来的。在其余的18种癌症中,所有癌症均被分类为T1A-C或T2A期,且均未分化或转移不良。如果排除了拒绝初次活检的七名患者,则相对于对照组癌症间隔癌的比例为18.5%(25/135)或13.3%(18/135)。当考虑所有25种间期癌症时,筛查方案的敏感性为79.8%,考虑到18种间期癌症时为85.5%。结论:四年筛查间隔的癌症发生率较低,这证明筛查方法具有较高的敏感性,并且四年筛查间隔是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号